Trial Profile
An open-label, fixed-sequence, 3-period study to evaluate the pharmacokinetics of elbasvir and buprenorphine/naloxone co-administration in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2016
Price :
$35
*
At a glance
- Drugs Buprenorphine/naloxone (Primary) ; Elbasvir (Primary)
- Indications Hepatitis C; Opioid-related disorders
- Focus Pharmacokinetics
- Sponsors Merck & Co
- 14 Mar 2016 New trial record